Emricasan (DB05408): A Comprehensive Monograph on a Pan-Caspase Inhibitor from Preclinical Promise to Clinical Discontinuation in Liver Disease

Executive Summary

Emricasan (DB05408) is an investigational, first-in-class, orally active, irreversible pan-caspase inhibitor. It was developed with the primary therapeutic goal of treating chronic liver diseases, particularly non-alcoholic steatohepatitis (NASH), by targeting the fundamental pathological processes of apoptosis and inflammation. The scientific rationale for Emricasan was compelling: by broadly inhibiting caspases—a family of enzymes central to programmed cell death and inflammatory signaling—the drug was designed to protect hepatocytes from excessive apoptosis, thereby reducing liver injury, inflammation, and the subsequent progression to fibrosis and cirrhosis.

This hypothesis was strongly supported by a robust body of preclinical evidence across various animal models of liver disease, where Emricasan consistently demonstrated potent anti-apoptotic, anti-inflammatory, and anti-fibrotic effects. Its unique pharmacokinetic profile, characterized by high first-pass hepatic uptake, positioned it as a "liver-targeted" agent, intended to maximize efficacy in the target organ while minimizing systemic exposure. These promising data propelled the drug into extensive clinical development and attracted a landmark collaboration between Conatus Pharmaceuticals and Novartis, signaling significant confidence in its potential.

Despite this strong preclinical foundation and major pharmaceutical backing, the pivotal Phase 2b ENCORE (EmricasaN, a Caspase inhibitOR, for Evaluation) clinical program, which evaluated Emricasan across the spectrum of NASH from fibrosis to decompensated cirrhosis, failed to demonstrate clinical efficacy. The ENCORE-NF trial in patients with NASH fibrosis did not meet its primary endpoint of histological improvement and, concerningly, suggested a potential worsening of fibrosis and hepatocyte ballooning. The ENCORE-PH trial failed to show a significant reduction in portal hypertension in patients with NASH cirrhosis. Finally, the ENCORE-LF trial in patients with decompensated NASH cirrhosis did not improve event-free survival. These definitive negative results led to the discontinuation of the Emricasan program for liver disease in 2019. The journey of Emricasan serves as a critical case study in the challenges of translational medicine, illustrating the profound disconnect that can exist between promising preclinical data and outcomes in complex human disease. Its failure provides valuable lessons regarding the therapeutic strategy of targeting apoptosis in NASH and the limitations of surrogate biomarkers in predicting clinical benefit.

Drug Identification and Physicochemical Properties

This section provides a definitive catalog of the chemical, structural, and physical properties of Emricasan, establishing its identity and the foundational characteristics that govern its pharmacological and pharmacokinetic behavior.

Core Identifiers and Synonyms

Emricasan is a small molecule drug that has been assigned numerous identifiers throughout its development lifecycle across several pharmaceutical companies and international databases.[1] Its primary identifiers are:

• Generic Name: Emricasan [2]
• DrugBank ID: DB05408 [1]
• CAS Number: 254750-02-2 [1]
• Deprecated CAS Number: 624747-15-5 [1]

Reflecting its passage through different corporate development programs, it is also known by several developmental codes and synonyms:

• IDN-6556 (from Idun Pharmaceuticals) [1]
• PF-03491390 (from Pfizer) [1]
• VAY785 (from Novartis) [1]
• Other synonyms include emricasán and emricasanum.[1]

Table 1: Chemical and Drug Identifiers for Emricasan

Identifier Type	Value	Source(s)
CAS Number	254750-02-2	1
DrugBank ID	DB05408	1
UNII	P0GMS9N47Q	1
ChEMBL ID	CHEMBL197672	1
KEGG ID	D10004	1
PubChem CID	12000240	6
NCI Thesaurus Code	C76660	1
IUPHAR/BPS Ligand ID	6508	5
DSSTox Substance ID	DTXSID10180160	1

Chemical and Structural Data

Emricasan is a synthetic organic compound classified as a peptidomimetic or hybrid peptide, designed to interact with enzyme targets typically bound by natural peptides.[2]

• Molecular Formula: C26​H27​F4​N3​O7​ [1]
• Molecular Weight: Approximately 569.51 g/mol [2]
• Monoisotopic Mass: 569.17851286 Da [1]
• IUPAC Name: (3S)-3-amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid [1]
• SMILES (Isomeric): CC(C(=O)N[C@H](CC(=O)O)C(=O)COc1c(c(cc(c1F)F)F)F)NC(=O)C(=O)Nc2ccccc2C(C)(C)C [6]
• InChIKey: SCVHJVCATBPIHN-SJCJKPOMSA-N [2]

Physicochemical Properties

The physicochemical characteristics of Emricasan are critical for understanding its formulation, route of administration, and pharmacokinetic profile. It presents as a white to off-white solid powder.[3] Its properties are indicative of a lipophilic, acidic molecule with poor aqueous solubility, characteristics that profoundly influenced its development as a liver-targeted agent.

• Water Solubility: 0.00213 mg/mL (very low) [2]
• logP (Octanol-Water Partition Coefficient): 3.42 - 3.48, indicating high lipophilicity [2]
• pKa (Strongest Acidic): 3.51 [2]
• pKa (Strongest Basic): -4.3 [2]
• Polar Surface Area: 150.9 A˚2 [2]
• Solubility in Organic Solvents: Soluble in DMSO (up to 257.5 mg/mL) and ethanol (up to 93 mg/mL), often requiring sonication for complete dissolution at high concentrations.[4]

The combination of low aqueous solubility and high lipophilicity is a key determinant of a drug's absorption and distribution. For an orally administered drug, these properties often predict low systemic bioavailability due to poor dissolution in the gastrointestinal tract and a high propensity for first-pass metabolism in the liver. This chemical profile aligns perfectly with the observed pharmacokinetic behavior of Emricasan, suggesting that its molecular structure was rationally designed to achieve high concentrations in the liver at the expense of systemic exposure, a strategy central to its therapeutic concept.[3]

Pharmacology and Mechanism of Action

Emricasan was developed based on a clear and compelling pharmacological hypothesis: that inhibiting the excessive apoptosis and inflammation driving chronic liver disease could halt or reverse its progression. Its mechanism of action is that of a potent, orally active, and irreversible pan-caspase inhibitor.[3]

Primary Mechanism: Pan-Caspase Inhibition

Caspases are a family of intracellular cysteine proteases that play a central role in mediating programmed cell death (apoptosis) and regulating inflammatory responses.[14] The term "pan-caspase inhibitor" signifies that Emricasan was designed to broadly inhibit the activity of multiple caspases, thereby conferring both anti-apoptotic and anti-inflammatory effects.[6]

The key targets of Emricasan within the caspase family include:

• Executioner Caspases (Caspase-3, -7): These are the final effectors in the apoptotic cascade, responsible for cleaving numerous cellular substrates and dismantling the cell in an orderly, non-inflammatory manner. By irreversibly inhibiting Caspase-3 and Caspase-7, Emricasan was intended to directly prevent hepatocyte death, the primary insult in many liver diseases.[2] Preclinical and clinical studies confirmed that Emricasan treatment reduces the activity of Caspase-3 and -7.[4]
• Initiator Caspases (Caspase-8, -9): These caspases act upstream to activate the executioner caspases. Caspase-8 is involved in the extrinsic (death receptor-mediated) apoptotic pathway, while Caspase-9 is central to the intrinsic (mitochondrial) pathway. Preclinical studies demonstrated that Emricasan attenuates the activity of Caspase-8 in models of NASH.[4]
• Inflammatory Caspases (Caspase-1): Distinct from the apoptotic caspases, Caspase-1 is a key component of the inflammasome, a protein complex that drives inflammation. It functions by cleaving the precursors of potent pro-inflammatory cytokines, interleukin-1 beta (IL-1β) and interleukin 18 (IL-18), into their active forms.[2] By inhibiting Caspase-1, Emricasan was expected to reduce the sterile inflammation that is a critical contributor to the progression of NASH and liver fibrosis.[15]

Downstream Pharmacodynamic Effects

The inhibition of these multiple caspase targets was hypothesized to interrupt the vicious cycle of liver injury. In chronic liver diseases like NASH, lipotoxicity and other stressors trigger hepatocyte apoptosis. The resulting apoptotic bodies are cleared by neighboring cells, including hepatic stellate cells (HSCs) and Kupffer cells (liver macrophages), which in turn become activated, promoting inflammation and fibrogenesis.[14]

By blocking this initial trigger—hepatocyte apoptosis—Emricasan was expected to produce several beneficial downstream effects:

1. Reduced Hepatocellular Injury: Directly preventing cell death would lower the release of liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST).[14]
2. Decreased Apoptotic Biomarkers: Inhibition of Caspase-3 and -7 would reduce the cleavage of their substrates, most notably cytokeratin-18 (CK18). The resulting fragment, cleaved CK18 (cCK18), is a specific biomarker of apoptosis, and its reduction was a key measure of target engagement for Emricasan.[14]
3. Suppression of Inflammation and Fibrosis: By reducing the number of apoptotic bodies and inhibiting inflammatory caspase activity, Emricasan was expected to decrease the activation of HSCs and dampen the overall inflammatory milieu, thereby slowing or halting the deposition of scar tissue (fibrosis).[14]

While the therapeutic rationale for pan-caspase inhibition appeared robust, this broad-spectrum approach may have concealed a critical flaw. Caspases are essential for maintaining cellular homeostasis, and apoptosis represents a controlled, non-inflammatory method for removing damaged cells. When this primary pathway is blocked, severely damaged cells must still be eliminated. Evidence from the clinical trials, particularly the observation of potentially worsened fibrosis and hepatocyte ballooning in the ENCORE-NF study, raises the possibility that inhibiting apoptosis shunted damaged hepatocytes toward alternative, more inflammatory cell death pathways, such as necroptosis.[18] This is supported by separate preclinical research demonstrating that Emricasan, in combination with other agents, can be used to

induce necroptosis as a potential cancer therapy.[6] Therefore, the very mechanism intended to be protective—broad caspase inhibition—may have inadvertently promoted a more pro-fibrotic and damaging form of cell death in the complex biological environment of human NASH, representing a fundamental reason for its translational failure.

Pharmacokinetics, Metabolism, and Liver-Targeting Profile (ADME)

The pharmacokinetic profile of Emricasan is a central aspect of its design and therapeutic strategy. Studies characterizing its absorption, distribution, metabolism, and excretion (ADME) reveal a molecule engineered for preferential delivery to the liver, its primary site of action.[11]

Absorption and Bioavailability

Following oral administration, Emricasan is poorly absorbed into the systemic circulation. Preclinical pharmacokinetic studies in rats demonstrated a low absolute oral bioavailability, ranging from 2.7% to 4%.[11] This limited systemic exposure is a direct consequence of its physicochemical properties, including very low aqueous solubility, and extensive first-pass metabolism in the liver.[2] While this would be a significant drawback for a drug requiring high systemic concentrations, for Emricasan it was an integral part of its liver-targeting design.

Distribution and Liver-Targeting

The most distinctive feature of Emricasan's pharmacokinetic profile is its preferential distribution to the liver. Despite low systemic bioavailability, studies in rats showed that drug concentrations in the portal vein (which drains from the intestine to the liver) were three-fold higher than those in the systemic circulation after an oral dose.[11] This indicates that the drug is efficiently absorbed from the gut into the portal system and is then rapidly extracted by the liver.

This high first-pass uptake results in sustained, high concentrations of Emricasan within the liver tissue. Liver concentrations remained constant for at least four hours after oral administration, reaching a maximum concentration (Cmax​) of 2558 ng/g at 120 minutes in one rat study.[11] This profile confirms its characterization as a "liver-targeted" caspase inhibitor, a design intended to maximize pharmacodynamic effects within the target organ while minimizing potential off-target effects associated with systemic drug exposure.[3]

Metabolism

The significant first-pass effect and high liver concentrations strongly imply that Emricasan undergoes extensive hepatic metabolism.[21] The liver's microsomal enzymes, particularly the cytochrome P450 system, are responsible for the biotransformation of most lipophilic drugs into more water-soluble metabolites that can be readily excreted.[21] While the specific metabolic pathways and metabolites of Emricasan are not detailed in the available documentation, its rapid clearance from systemic circulation and high hepatic extraction are classic indicators of a drug that is a substrate for robust hepatic metabolism.[11]

Excretion

Preclinical data from rats provide insight into Emricasan's excretion pathways. Following intravenous administration, a substantial portion of the parent drug (51%) was recovered intact in the bile, indicating that biliary excretion is a major route of elimination for the systemically available drug.[11] However, after oral administration, only a small fraction (4.9%) was excreted unchanged in the bile, a finding consistent with the extensive first-pass metabolism that limits the amount of parent drug reaching the biliary system.[11]

The liver-targeted design of Emricasan, while elegant from a pharmacological standpoint, may have been a strategic miscalculation for the treatment of advanced liver disease. Conditions such as NASH cirrhosis are not purely intrahepatic; they involve critical systemic and extrahepatic pathologies, most notably portal hypertension. Portal hypertension is driven both by increased resistance within the liver and by increased blood flow from the splanchnic circulation (the gut) into the portal vein.[17] Pathological processes mediated by caspases, such as the release of pro-inflammatory microparticles, are known to contribute to these extrahepatic hemodynamic disturbances.[17] A drug with minimal systemic exposure would be inherently limited in its ability to address these systemic drivers of the disease. The failure of the ENCORE-PH trial to significantly reduce the hepatic venous pressure gradient (HVPG), a key measure of portal pressure, supports the hypothesis that an exclusively liver-targeted approach may be insufficient for a disease with such significant systemic components.[25]

Preclinical Evidence in Models of Liver Disease

The advancement of Emricasan into large-scale clinical trials was underpinned by a substantial and consistently positive body of preclinical evidence. In various animal models of both acute and chronic liver disease, Emricasan demonstrated potent hepatoprotective, anti-inflammatory, and anti-fibrotic activity, providing a strong scientific rationale for its development.

Efficacy in Acute Liver Injury Models

In rodent models designed to mimic acute, apoptosis-driven liver failure, Emricasan showed marked efficacy. In the mouse anti-Fas antibody model and the rat D-galactosamine/lipopolysaccharide (D-Gln/LPS) model, administration of Emricasan resulted in a potent, dose-dependent reduction in serum alanine aminotransferase (ALT) levels, hepatocyte apoptosis, and caspase activity.[4] The drug was effective across multiple routes of administration (intraperitoneal, intravenous, and oral), with calculated median effective doses (

ED50​) in the highly potent sub-milligram per kilogram range.[11] These studies established its fundamental ability to inhibit caspase-mediated liver cell death

in vivo.

Efficacy in Chronic Liver Disease and NASH Models

More relevant to its intended clinical indication, Emricasan was evaluated in a murine model of non-alcoholic steatohepatitis (NASH) induced by a high-fat diet (HFD). In this chronic disease model, Emricasan treatment produced comprehensive benefits [3]:

• Anti-Apoptotic Effect: HFD-fed mice exhibited a five-fold increase in hepatocyte apoptosis and elevated activity of Caspase-3 and Caspase-8. Emricasan treatment substantially attenuated this increase in apoptosis and caspase activity.[4]
• Reduced Liver Injury and Inflammation: Treatment with Emricasan significantly reduced serum levels of ALT and AST. It also decreased the hepatic expression of key pro-inflammatory cytokines, including interleukin 1-beta (IL-1β) and tumor necrosis factor-alpha (TNF-α).[4]
• Anti-Fibrotic Effect: Critically, Emricasan demonstrated a direct effect on liver fibrosis, the pathological scarring that leads to cirrhosis. Treatment reduced the activation of hepatic stellate cells (the primary collagen-producing cells in the liver), as measured by decreased α-smooth muscle actin (αSMA) expression. This translated to lower overall fibrosis scores, reduced collagen deposition (measured by Sirius red staining and hydroxyproline content), and decreased expression of profibrogenic cytokines.[3] The anti-fibrotic effect was believed to be a direct result of inhibiting the primary injury of hepatocyte apoptosis, which is a major trigger for fibrosis.[15]

Effects on Portal Hypertension

In preclinical models of cirrhosis and portal hypertension induced by common bile duct ligation (BDL) in mice, Emricasan treatment improved survival and significantly reduced portal pressure.[17] This hemodynamic improvement was associated with a reduction in circulating microparticles, which are released from damaged cells and contribute to vascular dysfunction both within and outside the liver.[24] These findings suggested that Emricasan could address not only the structural (fibrosis) but also the functional (hemodynamic) consequences of advanced liver disease.

Table 2: Summary of Key Preclinical Studies and Outcomes for Emricasan

Model Type	Animal Model	Key Findings	Source(s)
Acute Liver Injury	Mouse anti-Fas Antibody	Marked reduction in ALT, apoptosis, and caspase activity; potent ED50​ values.	4
Acute Liver Injury	Rat D-Gln/LPS	Significant reduction in ALT activities after oral and IP administration.	4
NASH / Fibrosis	Murine High-Fat Diet	Attenuated hepatocyte apoptosis (reduced Caspase-3 & -8); reduced ALT/AST and inflammation (IL-1β, TNF-α); decreased fibrosis (reduced αSMA, Sirius red, hydroxyproline).	3
Cirrhosis / Portal Hypertension	Murine Bile Duct Ligation	Reduced portal pressure, decreased fibrosis, and improved survival; associated with a decrease in circulating microparticles.	17
Liver Preservation	Rat Cold Ischemia-Warm Reperfusion	Prevented sinusoidal endothelial cell apoptosis and inhibited Caspase-3 activation.	4

The breadth and consistency of these positive preclinical results created a powerful narrative, suggesting that Emricasan was a highly promising therapeutic candidate capable of modifying the course of liver disease by targeting its fundamental mechanisms. This strong foundation provided the justification for the large and ambitious ENCORE clinical program in humans.

The ENCORE Clinical Program in NASH: Design and Results

The ENCORE (EmricasaN, a Caspase inhibitOR, for Evaluation) program represented the definitive clinical assessment of Emricasan's efficacy in patients with NASH. This series of three large, randomized, double-blind, placebo-controlled Phase 2b trials was conducted by Conatus Pharmaceuticals in collaboration with Novartis and was designed to evaluate the drug across the full spectrum of disease severity, from moderate fibrosis to decompensated cirrhosis.[33] Despite the strong preclinical rationale, the entire program ultimately failed to demonstrate a clinical benefit, leading to the termination of Emricasan's development for liver disease.

Table 3: Overview of the ENCORE Clinical Trial Program

Trial Name	NCT Identifier	Patient Population	N	Doses (BID)	Duration	Primary Endpoint
ENCORE-NF	NCT02686762	NASH with Fibrosis (F1-F3)	318	5 mg, 50 mg, Placebo	72 weeks	≥1 stage fibrosis improvement without worsening NASH
ENCORE-PH	NCT02960204	NASH Cirrhosis with Severe Portal Hypertension (HVPG ≥12 mmHg)	263	5 mg, 25 mg, 50 mg, Placebo	24 weeks	Change in Hepatic Venous Pressure Gradient (HVPG)
ENCORE-LF	NCT03205345	Decompensated NASH Cirrhosis	217	5 mg, 25 mg, Placebo	≥48 weeks	Event-Free Survival (composite clinical endpoint)

ENCORE-NF (NASH Fibrosis; NCT02686762)

The ENCORE-NF trial was designed to test the hypothesis that Emricasan could reverse or halt the progression of liver fibrosis in patients with non-cirrhotic NASH.

• Design: The study enrolled 318 patients with biopsy-confirmed NASH and fibrosis stages F1, F2, or F3. Patients were randomized in a 1:1:1 ratio to receive Emricasan 5 mg twice daily (BID), Emricasan 50 mg BID, or a matching placebo for 72 weeks.[18]
• Primary Endpoint: The primary objective was to demonstrate a statistically significant improvement of at least one stage in the NASH Clinical Research Network (CRN) fibrosis score with no worsening of steatohepatitis at week 72.[18]
• Results: The trial unequivocally failed to meet its primary endpoint. The proportion of patients achieving fibrosis improvement was numerically lower in both Emricasan arms compared to the placebo arm. The response rates were 11.2% for the 5 mg group and 12.3% for the 50 mg group, versus 19.0% for the placebo group.[18] The secondary endpoint of NASH resolution without worsening of fibrosis was also not met.[18]
• Analysis: This result was particularly concerning because it not only showed a lack of efficacy but also suggested a trend towards a worse histological outcome. While the study did confirm target engagement through significant reductions in serum ALT and caspase levels, this did not translate to a histological benefit.[37] The investigators concluded that long-term caspase inhibition, while reducing a marker of liver injury like ALT, may have paradoxically promoted alternative, more detrimental cell death pathways, leading to increased hepatocyte ballooning and fibrosis.[18]

ENCORE-PH (Portal Hypertension; NCT02960204)

The ENCORE-PH trial aimed to determine if Emricasan could reduce portal pressure, a major driver of complications in patients with cirrhosis.

• Design: The study enrolled 263 patients with either compensated or early decompensated NASH cirrhosis and severe portal hypertension, defined as a hepatic venous pressure gradient (HVPG) of ≥12 mmHg. Patients were randomized 1:1:1:1 to receive Emricasan (5 mg, 25 mg, or 50 mg BID) or placebo for 24 weeks, with an optional 24-week extension period.[25]
• Primary Endpoint: The primary endpoint was the change in mean HVPG from baseline to week 24 for any of the Emricasan groups compared with placebo.[25]
• Results: The trial failed to meet its primary endpoint. There were no statistically significant differences in the change in HVPG between any of the Emricasan dose groups and the placebo group at 24 weeks.[25] Post-hoc analyses suggested some favorable, non-significant trends in the subgroup of compensated patients with the highest baseline portal pressure (HVPG ≥16 mmHg), but these were insufficient to demonstrate efficacy.[26] Data from the 24-week extension period confirmed the initial findings, showing no sustained treatment effect.[25]
• Analysis: As in the ENCORE-NF trial, Emricasan treatment led to significant reductions in biomarkers of apoptosis and inflammation at week 24. However, this effect was not sustained at week 48 and, more importantly, did not translate into a meaningful improvement in the key hemodynamic measure of HVPG or in clinical outcomes.[26]

ENCORE-LF (Liver Function; NCT03205345)

The ENCORE-LF trial was the most ambitious of the three, designed to evaluate whether Emricasan could improve hard clinical outcomes in the sickest patient population: those with decompensated NASH cirrhosis.

• Design: The study enrolled 217 patients with decompensated NASH cirrhosis. Patients were randomized to receive Emricasan (5 mg or 25 mg BID) or placebo for at least 48 weeks.[25]
• Primary Endpoint: The primary endpoint was a composite clinical outcome of event-free survival, defined as the time to all-cause mortality, the occurrence of a new decompensation event, or a progression of ≥4 points in the Model for End-stage Liver Disease (MELD) score.[25]
• Results: The trial failed to meet its primary endpoint. The primary analysis, conducted after a target number of events was reached, showed no statistically significant difference in event-free survival rates between the Emricasan treatment arms and the placebo arm.[25] Following these definitive negative results, Conatus announced the discontinuation of further treatment for all patients enrolled in the trial.[25]
• Analysis: The failure to show a benefit on a hard clinical endpoint in patients with the most advanced disease was the final confirmation that Emricasan was not an effective therapy for NASH. This outcome led to the termination of the collaboration with Novartis and the entire Emricasan development program for liver disease.

Table 4: Summary of Primary Endpoint Results from the ENCORE Trials

Trial	Primary Endpoint	Placebo Group Result	Emricasan Group(s) Result	Outcome
ENCORE-NF	Fibrosis Improvement ≥1 Stage	19.0%	5 mg: 11.2% 50 mg: 12.3%	Not Met
ENCORE-PH	Change in HVPG at 24 Weeks	-0.21 mmHg (adjusted)	No significant difference vs. placebo for any dose group.	Not Met
ENCORE-LF	Event-Free Survival	No statistically significant difference vs. treatment arms.	No statistically significant difference vs. placebo.	Not Met

Exploratory Investigations in Other Therapeutic Areas

While the primary focus of Emricasan's development was liver disease, its mechanism as a pan-caspase inhibitor with anti-apoptotic and anti-inflammatory properties prompted exploratory research in several other disease areas. These investigations were generally preclinical or early-phase and did not lead to advanced clinical programs.

• COVID-19: A Phase 1 clinical trial (NCT04803227) was initiated to assess the safety and tolerability of Emricasan in symptomatic outpatients with mild COVID-19.[44] The rationale was likely to target the apoptosis and hyperinflammation associated with SARS-CoV-2 infection. However, this trial was ultimately terminated before completion.[44]
• Acute Myeloid Leukemia (AML): Preclinical studies explored a novel therapeutic strategy using Emricasan in combination with a SMAC mimetic agent called birinapant. This combination was found to induce necroptosis, a form of programmed necrosis, in AML cells, suggesting a potential anti-cancer application by leveraging an alternative cell death pathway when apoptosis is inhibited.[6]
• Zika Virus (ZIKV) Infection: In vitro research demonstrated that Emricasan could inhibit the increase in Caspase-3 activity induced by Zika virus infection.[9] This action protected human cortical neural progenitors and astrocytes from ZIKV-induced cell death, preserving cell viability and suggesting a potential role in mitigating the neurological damage caused by the virus.[9]
• Fuchs Endothelial Corneal Dystrophy (FECD): More recent research has investigated Emricasan as a potential pharmacological therapy for FECD, a degenerative eye disease characterized by corneal endothelial cell death. In vitro and in vivo studies showed that Emricasan could reduce both apoptosis and the pathological accumulation of extracellular matrix by selectively inhibiting Caspase-7, suggesting a dual protective effect.[46]
• Stem Cell Biology: In a non-therapeutic application, Emricasan has found a niche use in cell culture. It is a key component of a small molecule cocktail known as CEPT (Chroman 1, Emricasan, Polyamines, and Trans-ISRIB). This cocktail synergistically improves the survival, viability, and clonogenicity of human pluripotent stem cells (hPSCs) following stressful procedures like single-cell dissociation, gene editing, and cryopreservation.[9]

Comprehensive Safety and Tolerability Profile

A critical aspect of Emricasan's clinical development story is its safety profile. Across an extensive program that included 19 completed clinical trials and over 950 subjects, Emricasan was consistently found to be generally safe and well-tolerated, with a safety profile comparable to that of placebo.[16]

Clinical Safety Data

In the pivotal ENCORE trials, the overall incidence and types of adverse events were similar between the Emricasan and placebo groups.[25] A systematic review and meta-analysis of clinical trials in patients with liver cirrhosis or fibrosis found no significant increase in the rate of overall adverse events with Emricasan treatment compared to placebo (Odds Ratio 1.52).[14] In one study of patients with cirrhosis, fatigue was reported as the most common adverse event, occurring in 22% of participants, but there were no deaths or decompensating events attributed to the drug.[17] The consistent and favorable safety profile demonstrated that the discontinuation of Emricasan's development was driven solely by a lack of efficacy, not by safety or tolerability concerns.

Carcinogenicity Assessment

A long-standing theoretical concern with anti-apoptotic therapies is the potential for interfering with normal cellular turnover and promoting the survival of malignant cells, thereby increasing the risk of cancer.[16] To address this, a dedicated 26-week carcinogenicity study was conducted in the Tg.rasH2 transgenic mouse model, which is sensitive to carcinogens.[51] The study found no evidence of Emricasan-related tumor formation in any tissue, even at the highest dose tested (75 mg/kg/day). While some non-neoplastic lesions were observed, they were not considered pre-neoplastic. The study concluded that Emricasan is not carcinogenic, providing crucial safety data that supported its continued clinical investigation.[51]

Corporate Development and Regulatory Trajectory

The history of Emricasan is marked by a series of corporate acquisitions and a major collaboration, reflecting the high level of initial scientific and commercial interest in its novel mechanism of action. Its regulatory path was similarly promising, characterized by special designations from the U.S. Food and Drug Administration (FDA) that highlighted the significant unmet medical need it aimed to address.

Corporate Development Timeline

Emricasan's journey through the pharmaceutical industry spanned over two decades and involved several key players:

• 1998: Invented by Idun Pharmaceuticals, a company focused on controlling apoptosis.[6]
• 2005: Acquired by Pfizer as part of its acquisition of Idun Pharmaceuticals.[6]
• 2010: Pfizer sold the asset to Conatus Pharmaceuticals, a biotechnology company focused on liver disease. Conatus became the primary driver of Emricasan's clinical development.[6]
• December 2016: Conatus entered into a landmark exclusive option, collaboration, and license agreement with Novartis for the global development and commercialization of Emricasan. The deal included a $50 million upfront payment to Conatus, signaling strong validation from a major pharmaceutical company.[34]
• May 2017: Novartis exercised its option to license Emricasan, triggered by the initiation of the ENCORE-LF trial. This involved an additional $7 million payment to Conatus and committed Novartis to funding and conducting potential Phase 3 studies if the Phase 2b program proved successful.[55]
• 2018-2019: A series of negative trial results were announced, starting with ENCORE-PH in December 2018, followed by ENCORE-NF, and culminating with the failure of ENCORE-LF in June 2019. These results led to the termination of the clinical program and the collaboration.[25]

Table 5: Timeline of Key Corporate and Regulatory Milestones for Emricasan

Date / Year	Event	Significance
1998	Invented by Idun Pharmaceuticals.	Origin of the first-in-class pan-caspase inhibitor.
2005	Acquired by Pfizer.	Integration into a major pharmaceutical company's pipeline.
2010	Acquired by Conatus Pharmaceuticals.	Shift in focus to dedicated development for chronic liver disease.
Nov 2013	FDA grants Orphan Drug Designation.	Acknowledges potential for a rare disease subpopulation (post-transplant fibrosis).
Dec 2016	Conatus and Novartis sign collaboration agreement.	Major validation and financial backing; Novartis receives option for global rights.
May 2017	Novartis exercises its option to license Emricasan.	Full commitment from Novartis to advance the drug into Phase 3 if ENCORE trials succeed.
Dec 2018	ENCORE-PH trial fails to meet primary endpoint.	First major clinical setback; fails to show benefit in portal hypertension.
Early 2019	ENCORE-NF trial fails to meet primary endpoint.	Second major failure; fails to show histological benefit in NASH fibrosis.
June 2019	ENCORE-LF trial fails to meet primary endpoint.	Definitive clinical failure in decompensated cirrhosis; program is discontinued.

Regulatory Status and Designations

Emricasan remains an investigational drug and has not received marketing approval from any regulatory agency worldwide.[6] However, it received several important regulatory designations during its development.

• U.S. Food and Drug Administration (FDA):
• Investigational New Drug (IND): Emricasan has active IND status in the United States, allowing it to be tested in clinical trials.[6]
• Fast Track Designation: The FDA granted Fast Track designation for the development of Emricasan for the treatment of patients with NASH cirrhosis. This status is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.[6]
• Orphan Drug Designation: On November 20, 2013, the FDA granted Orphan Drug Designation to Emricasan for the "treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease".[56] This designation provides incentives for the development of drugs for rare diseases affecting fewer than 200,000 people in the U.S.
• European Medicines Agency (EMA): Emricasan has not been granted marketing authorization in the European Union. The available information indicates it was the subject of a paediatric investigation plan (PIP) in the therapeutic area of gastroenterology-hepatology, with a decision on the plan made in July 2019.[1] There is no evidence that a formal marketing authorization application was ever submitted to the EMA.[59]
• Therapeutic Goods Administration (TGA): There is no information to suggest that Emricasan was ever submitted for regulatory review or approval in Australia.[61]

Expert Analysis and Future Outlook

The clinical development of Emricasan for chronic liver disease stands as a significant and cautionary chapter in pharmaceutical research. Its journey from a molecule with a compelling mechanism and robust preclinical validation to its definitive failure in a large, well-executed clinical program offers critical lessons for the field of hepatology and drug development at large.

The Great Translational Failure: From Preclinical Success to Clinical Disappointment

The most striking aspect of the Emricasan story is the profound disconnect between its consistent success in animal models and its complete lack of efficacy in human trials. In preclinical models of NASH, Emricasan reliably reduced apoptosis, inflammation, and fibrosis.[15] In human patients with NASH, it did none of these things in a clinically meaningful way; in the ENCORE-NF trial, it may have even worsened key histological features.[18] This stark divergence points to two potential, non-mutually exclusive causes. First, it questions the predictive validity of the preclinical models used. Rodent models of NASH, while useful for studying specific pathways, may not adequately recapitulate the decades-long, metabolically complex, and heterogeneous nature of human fibrotic liver disease. Second, and perhaps more fundamentally, it challenges the central therapeutic hypothesis itself. The assumption that broadly inhibiting apoptosis would be sufficient to halt fibrosis in established human disease may have been an oversimplification. As discussed, blocking this controlled form of cell death may have inadvertently promoted more damaging, pro-inflammatory pathways like necroptosis, a hypothesis supported by the histological outcomes in ENCORE-NF.

The Biomarker Conundrum and the Limits of Target Engagement

Emricasan's development is a classic example of the "biomarker conundrum," where a drug successfully engages its molecular target but fails to produce a clinical benefit. Across the ENCORE trials, Emricasan consistently and significantly reduced serum levels of ALT, AST, and caspase activity biomarkers like cCK18.[17] This confirmed that the drug was reaching the liver in sufficient concentrations to exert a pharmacodynamic effect. However, this target engagement did not translate into any improvement in liver histology, hemodynamics (portal pressure), or clinical outcomes. This outcome serves as a powerful reminder that surrogate biomarkers, particularly those reflecting only acute injury (like ALT), are not reliable predictors of long-term changes in the complex structural pathology of fibrosis or the hard clinical endpoints of decompensation and death. The Emricasan data have contributed significantly to a field-wide re-evaluation of the endpoints required to demonstrate meaningful efficacy in NASH trials.

Implications for Caspase Inhibition as a Therapeutic Strategy

As the first pan-caspase inhibitor to undergo broad and rigorous clinical testing for liver disease, Emricasan's failure has cast a long shadow over this therapeutic class.[6] The results suggest that a non-selective, "pan-inhibition" approach to modulating cell death is likely too blunt an instrument for a chronic, complex disease. The intricate roles of different caspases in both pathological and homeostatic processes mean that broad inhibition may carry unforeseen and detrimental consequences. Future research in this area may need to shift towards more nuanced and selective strategies, such as targeting only specific inflammatory caspases (e.g., Caspase-1) or modulating specific arms of the apoptotic pathway, rather than attempting to block the entire process.

Legacy and Concluding Thoughts

Despite its failure, the Emricasan program has left a valuable legacy. The ENCORE trials were large, methodologically sound studies that provided a definitive negative answer regarding the utility of pan-caspase inhibition in NASH. In a field characterized by high failure rates, such definitive data are crucial for preventing the further expenditure of resources on futile pathways and for guiding future research. The program generated a wealth of clinical and biomarker data that will continue to inform our understanding of NASH pathogenesis and trial design for years to come.

In conclusion, Emricasan represents a well-told story of the immense risks and challenges inherent in drug development. It began with an elegant scientific hypothesis, was supported by strong preclinical data, and was pursued through a high-quality clinical program backed by a major pharmaceutical collaboration. Its ultimate failure underscores the complexity of translating basic science into effective therapies for chronic human diseases and highlights the critical need for better preclinical models and more predictive clinical endpoints in the ongoing search for a treatment for non-alcoholic steatohepatitis.

Works cited

1. Emricasan | C26H27F4N3O7 | CID 12000240 - PubChem, accessed September 23, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Emricasan
2. Emricasan: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 23, 2025, https://go.drugbank.com/drugs/DB05408
3. Emricasan | IDN-6556 | PF-03491390 | CAS#254750-02-2 | Capase ..., accessed September 23, 2025, https://www.medkoo.com/products/6575
4. Emricasan (IDN-6556, PF-03491390, CAS Number: 254750-02-2) | Cayman Chemical, accessed September 23, 2025, https://www.caymanchem.com/product/22204/emricasan
5. Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice. - DGIdb, accessed September 23, 2025, https://dgidb.org/drugs/ncit:C76660
6. Emricasan - Wikipedia, accessed September 23, 2025, https://en.wikipedia.org/wiki/Emricasan
7. emricasan | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 23, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6508
8. CAS 254750-02-2 Emricasan - BOC Sciences, accessed September 23, 2025, https://www.bocsci.com/product/emricasan-cas-254750-02-2-74275.html
9. Technical Data Sheet - Emricasan - Captivate Bio, accessed September 23, 2025, https://captivatebio.com/store/pub/media/documents/products/small_molecules/Captivate-Bio-Emricasan-TDS-SML21.pdf
10. Emricasan | IDN-6556 | caspase inhibitor - TargetMol, accessed September 23, 2025, https://www.targetmol.com/compound/emricasan
11. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl ..., accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/14742742/
12. Emricasan (PF 03491390) | pan-Caspase Inhibitor - MedchemExpress.com, accessed September 23, 2025, https://www.medchemexpress.com/Emricasan.html
13. Emricasan, Caspase Inhibitor | Small Molecules - Captivate Bio, accessed September 23, 2025, https://captivatebio.com/store/emricasan-caspase-inhibitor.html
14. Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis | Clinics - Elsevier, accessed September 23, 2025, https://www.elsevier.es/en-revista-clinics-22-articulo-efficacy-safety-emricasan-in-liver-S1807593222000990
15. The Pan-Caspase Inhibitor Emricasan (IDN-6556) Decreases Liver Injury and Fibrosis in a Murine Model of Non-Alcoholic Steatohepatitis | Request PDF - ResearchGate, accessed September 23, 2025, https://www.researchgate.net/publication/261769695_The_Pan-Caspase_Inhibitor_Emricasan_IDN-6556_Decreases_Liver_Injury_and_Fibrosis_in_a_Murine_Model_of_Non-Alcoholic_Steatohepatitis
16. Emricasan - Cloudfront.net, accessed September 23, 2025, https://d1io3yog0oux5.cloudfront.net/_5d18aa398cf0f473dcf94e9e35e8b733/conatuspharma/db/424/3092/file/5079.pdf
17. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension - PMC - PubMed Central, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6587783/
18. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis - PubMed, accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/31887369/
19. Pharmacokinetics: Definition & Use in Drug Development - Allucent, accessed September 23, 2025, https://www.allucent.com/resources/blog/what-pharmacokinetics-and-adme
20. What are the main ADME processes in pharmacokinetics? - Patsnap Synapse, accessed September 23, 2025, https://synapse.patsnap.com/article/what-are-the-main-adme-processes-in-pharmacokinetics
21. Hepatic Drug Metabolism and Excretion - AccessAnesthesiology - McGraw Hill Medical, accessed September 23, 2025, https://accessanesthesiology.mhmedical.com/content.aspx?bookid=974§ionid=61590706
22. Drug Metabolism and Pharmacokinetics - Invitrocue - Transforming Bioanalytics, accessed September 23, 2025, https://www.invitrocue.com/preclinical-services/drug-metabolism-and-pharmacokinetics/
23. Drug Metabolism and Pharmacokinetics | BCM - Baylor College of Medicine, accessed September 23, 2025, https://www.bcm.edu/research/atc-core-labs/nmr-and-drug-metabolism-core/facility-and-services/drug-metabolism-and-pharmacokinetics
24. Emricasan, a pan caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation - eScholarship, accessed September 23, 2025, https://escholarship.org/content/qt11n5k8vm/qt11n5k8vm_noSplash_49670c39abb62b2da6539fd19df2903f.pdf
25. Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis - GlobeNewswire, accessed September 23, 2025, https://www.globenewswire.com/news-release/2019/06/24/1873299/0/en/Conatus-Announces-Results-from-ENCORE-LF-and-ENCORE-PH-Phase-2b-Clinical-Trials-in-NASH-Cirrhosis.html
26. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension - PubMed, accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/31870950/
27. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis - PubMed, accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/24750664/
28. The Pan-Caspase Inhibitor Emricasan (IDN-6556) Decreases Liver Injury and Fibrosis in a Murine - CORE, accessed September 23, 2025, https://core.ac.uk/download/pdf/158835036.pdf
29. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis - Mayo Clinic, accessed September 23, 2025, https://mayoclinic.elsevierpure.com/en/publications/the-pan-caspase-inhibitor-emricasan-idn-6556-decreases-liver-inju
30. Conatus Pharmaceuticals' Pan-Caspase Inhibitor Emricasan Improves Survival & Portal Hypertension - Drug Development and Delivery, accessed September 23, 2025, https://drug-dev.com/conatus-pharmaceuticals-pan-caspase-inhibitor-emricasan-improves-survival-portal-hypertension/
31. (PDF) Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation - ResearchGate, accessed September 23, 2025, https://www.researchgate.net/publication/324969042_Emricasan_a_pan-caspase_inhibitor_improves_survival_and_portal_hypertension_in_a_murine_model_of_common_bile-duct_ligation
32. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury - PubMed, accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/12619025/
33. CONATUS PHARMACEUTICALS INC. - AnnualReports.com, accessed September 23, 2025, https://www.annualreports.com/HostedData/AnnualReportArchive/h/NASDAQ_HSTO_2018.pdf
34. EdgarFiling - SEC.gov, accessed September 23, 2025, https://www.sec.gov/Archives/edgar/data/1383701/000117184317001533/exh_991.htm
35. Conatus announces top-line results from ENCORE-NF phase 2b clinical trial in NASH fibrosis - Pharmaceutical Business review, accessed September 23, 2025, https://www.pharmaceutical-business-review.com/news/conatus-announces-top-line-results-from-encore-nf-phase-2b-clinical-trial-in-nash-fibrosis/
36. Study Details | NCT02686762 | Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis | ClinicalTrials.gov, accessed September 23, 2025, https://www.clinicaltrials.gov/study/NCT02686762?term=caspase%20inhibitor&viewType=Table&rank=5
37. Novartis, Conatus' emricasan fails mid-stage NASH fibrosis trial - FirstWord Pharma, accessed September 23, 2025, https://firstwordpharma.com/story/4761299
38. Conatus Pharma Stock Craters After 3rd Failed NASH Trial - BioSpace, accessed September 23, 2025, https://www.biospace.com/conatus-pharma-s-nash-drug-fails-yet-another-trial
39. Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension | Clinical Research Trial Listing - CenterWatch, accessed September 23, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT04806750/emricasan-an-oral-caspase-inhibitor-in-subjects-with-non-alcoholic-steatohepatitis-nash-cirrhosis-and-severe-portal-hypertension
40. Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis, accessed September 23, 2025, https://www.pm360online.com/conatus-announces-results-from-encore-ph-phase-2b-clinical-trial-in-nash-cirrhosis/
41. Conatus Announces Completion Of Enrollment In ENCORE-LF Phase 2b Clinical Trial Of Emricasan In Patients With Decompensated NASH Cirrhosis, accessed September 23, 2025, https://www.clinicalleader.com/doc/conatus-announces-completion-enrollment-lf-clinical-trial-emricasan-patients-decompensated-nash-cirrhosis-0001
42. Nonalcoholic Steatohepatitis (NASH) Clinical Trials - Mayo Clinic Research, accessed September 23, 2025, https://www.mayo.edu/research/clinical-trials/diseases-conditions/nonalcoholic-steatohepatitis-(nash)
43. Novartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosis, accessed September 23, 2025, https://www.novartis.com/news/media-releases/novartis-provides-update-phase-2b-encore-lf-trial-nash-cirrhosis
44. COVID-19, SARS-CoV-2 Terminated Phase 1 Trials for Emricasan (DB05408) - DrugBank, accessed September 23, 2025, https://go.drugbank.com/indications/DBCOND0142914/clinical_trials/DB05408?phase=1&status=terminated
45. Emricasan - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 23, 2025, https://synapse.patsnap.com/drug/c35677766843458f880a52a807235d41
46. Therapeutic Potential of Emricasan, a Pan-Caspase Inhibitor, in Reducing Cell Death and Extracellular Matrix Accumulation in Fuchs Endothelial Corneal Dystrophy - MDPI, accessed September 23, 2025, https://www.mdpi.com/2073-4409/14/7/498
47. Therapeutic Potential of Emricasan, a Pan-Caspase Inhibitor, in Reducing Cell Death and Extracellular Matrix Accumulation in Fuchs Endothelial Corneal Dystrophy - PMC - PubMed Central, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11988121/
48. (PDF) Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis - ResearchGate, accessed September 23, 2025, https://www.researchgate.net/publication/352387134_Efficacy_and_Safety_of_Emricasan_in_Liver_Cirrhosis_andor_Fibrosis
49. Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis - PMC - PubMed Central, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8183342/
50. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With ..., accessed September 23, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587783/
51. Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice, accessed September 23, 2025, https://pubmed.ncbi.nlm.nih.gov/25896096/
52. Carcinogenicity assessment of the Pan-caspase Inhibitor, Emricasan, in Tg.rasH2 Mice. | Request PDF - ResearchGate, accessed September 23, 2025, https://www.researchgate.net/publication/275278714_Carcinogenicity_assessment_of_the_Pan-caspase_Inhibitor_Emricasan_in_TgrasH2_Mice
53. Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases, accessed September 23, 2025, https://www.novartis.com/news/media-releases/novartis-announces-exclusive-option-collaboration-and-license-agreement-conatus-develop-new-oral-treatments-chronic-liver-diseases
54. Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan - GlobeNewswire, accessed September 23, 2025, https://www.globenewswire.com/news-release/2016/12/19/898968/0/en/Conatus-Announces-Exclusive-Worldwide-Option-Collaboration-and-License-Agreement-Covering-Development-and-Commercialization-of-Emricasan.html
55. Novartis exercises exclusive option agreement with Conatus for the treatment of NASH, accessed September 23, 2025, https://www.novartis.com/news/media-releases/novartis-exercises-exclusive-option-agreement-conatus-treatment-nash
56. Search Orphan Drug Designations and Approvals - FDA, accessed September 23, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=396113
57. Conatus's liver drug emricasan gets FDA orphan drug status - Pharmaceutical Technology, accessed September 23, 2025, https://www.pharmaceutical-technology.com/uncategorized/newsconatuss-chronic-liver-disease-treatment-emricasan-gets-fda-orphan-drug-status-4139697/
58. Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver - Gilde Healthcare, accessed September 23, 2025, https://gildehealthcare.com/news/venture-and-growth/conatus-pharmaceuticals-receives-us-orphan-drug-designation-for-emricasan/
59. European Medicines Agency (EMA), accessed September 23, 2025, https://www.ema.europa.eu/en/medicines
60. Search | European Medicines Agency (EMA), accessed September 23, 2025, https://www.ema.europa.eu/en/search
61. Therapeutic Goods Administration (TGA) | Australian Government Department of Health, Disability and Ageing, accessed September 23, 2025, https://www.tga.gov.au/
62. Therapeutic Goods Administration - Wikipedia, accessed September 23, 2025, https://en.wikipedia.org/wiki/Therapeutic_Goods_Administration